Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 402
- Registration Number
- NCT05353361
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05347498
Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05336279
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC, Jinan, Jinan, China
The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy Subjects
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05336071
- Locations
- 🇨🇳
The Qian Foshan Hospital of Shandong Province, Jinan, Shandong, China
A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 455
- Registration Number
- NCT05333835
- Locations
- 🇨🇳
Peking university People's Hospital, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05324631
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT05320692
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of HRS4800 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery.
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT05318846
- Locations
- 🇨🇳
West China Hospital of Stomatology Sichuan University, Chengdu, Sichuan, China
A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 67
- Registration Number
- NCT05318833
A Trial of HR17031 Injection With Renal Insufficiency
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05292495
© Copyright 2024. All Rights Reserved by MedPath